Influence of RNA titre and amino acid changes in the NS5A region of GB virus C/hepatitis G virus on the effectiveness of interferon therapy
- 1 June 2000
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 15 (6) , 632-639
- https://doi.org/10.1046/j.1440-1746.2000.02196.x
Abstract
Background : A relationship between the pretreatment RNA titre of GB virus C/hepatitis G virus (GBV‐C/HGV) and the effectiveness of interferon (IFN) therapy has been reported previously. However, the influence of changes in the amino acid sequence of the NS5A region of GBV‐C/HGV on the effectiveness of IFN therapy has not been examined, although this influence has been explored in patients with chronic hepatitis caused by hepatitis C virus. We examined the relationship between changes in the amino‐acid sequence of the NS5A region and the effectiveness of IFN therapy. Methods : The subjects were 10 patients with chronic hepatitis C coinfected with GBV‐C/HGV and treated with IFN. The pretreatment level of GBV‐C/HGV‐RNA (copies/mL) in their sera was measured by real‐time detection polymerase chain reaction (PCR) assay. At 6 months after cessation of therapy, four of 10 patients had become negative for GBV‐C/HGV‐RNA (CR, complete response) and six patients were still positive for GBV‐C/HGV‐RNA (NR, non‐response). We determined the nucleotide sequence of the NS5A region (amino acid residues 1865–2279; NS5A1865–2279) of pretreatment GBV‐C/HGV‐RNA by direct sequencing. Results : The pretreatment GBV‐C/HGV‐RNA level of CR patients (7.8 × 104–6.2 × 105, mean 3.30 × 105) was significantly lower than that of NR patients (6.3 × 107–7.2 × 108, mean 3.55 × 108; P < 0.01). The number of amino acid substitutions in NS5A1865–2279 was five to seven (mean 5.8 ± 1.0) in CR patients, and four to eight (mean 6.8 ± 1.6) in NR patients, a difference that is not significant. Moreover, there were no amino acid substitutions or sites of substitution in NS5A1865–2279 that were specific to either group. Conclusions : The effectiveness of IFN therapy for GBV‐C/HGV is strongly related to the pretreatment GBV‐C/HGV‐RNA level, but is not related to changes in NS5A1865–2279.Keywords
This publication has 32 references indexed in Scilit:
- In situ detection of mutated hepatitis B virus in microdissected, formalinfixed liver tissues from patients with chronic hepatitis BJournal of Hepatology, 1999
- Mutations in Ns5a Region of Hepatitis C Virus Genome Correlate With Presence of Ns5a Antibodies and Response to Interferon Therapy for Most Common European Hepatitis C Virus GenotypesHepatology, 1998
- The “interferon sensitivity determining region” of hepatitis C virus is a stable sequence elementJournal of Hepatology, 1998
- Interferon-α therapy in patients dually infected with hepatitis C virus and GB virus C/hepatitis G virus — virological response of HGV and pretreatment HGV viremia levelJournal of Hepatology, 1997
- Hepatitis G virus infection in chronic hepatitis C: frequency, features and response to interferon therapyJournal of Hepatology, 1997
- GB virus C/hepatitis G virus infection among Japanese patients with chronic liver disease and blood donorsVirus Research, 1996
- GB virus C infection in fulminant and acute hepatitisInternational Hepatology Communications, 1996
- Sequence of Hepatitis G Virus Genome Isolated from a Japanese Patient with Non-A–E-Hepatitis: Amplification and Cloning by Long Reverse Transcription-PCRBiochemical and Biophysical Research Communications, 1996
- Sequence heterogeneity within the 5′-terminal region of the hepatitis GB virus C genome and evidence for genotypesJournal of Hepatology, 1996
- Alphabet of hepatitis virusesThe Lancet, 1996